Recent advances in infant botulism

Christine K. Fox, Corinne Keet, Jonathan B. Strober

Research output: Contribution to journalArticle

Abstract

Since infant botulism was first identified three decades ago, our understanding of botulinum toxins and the organisms that produce them has grown. A newer classification system now recognizes Clostridium baratii and Clostridium butyricum along with Clostridium botulinum as causative agents. Recently, increasing therapeutic use of botulinum toxins has sparked substantial new research into their mechanisms of action. This research, and some case reports from infants sickened by unusual botulinum toxins suggest that disease caused by different toxin types may result in varying clinical presentations. Perhaps most significantly for pediatricians and child neurologists, a specific treatment for infant botulism has just been approved. This article reviews the clinical presentation, diagnosis, and treatment of infant botulism, including human botulism immune globulin, and discusses the various organisms and toxins that cause this disease.

Original languageEnglish (US)
Pages (from-to)149-154
Number of pages6
JournalPediatric Neurology
Volume32
Issue number3
DOIs
StatePublished - Mar 2005
Externally publishedYes

Fingerprint

Botulism
Botulinum Toxins
Clostridium butyricum
Clostridium botulinum
Clostridium
Therapeutic Uses
Research
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Developmental Neuroscience
  • Neurology

Cite this

Recent advances in infant botulism. / Fox, Christine K.; Keet, Corinne; Strober, Jonathan B.

In: Pediatric Neurology, Vol. 32, No. 3, 03.2005, p. 149-154.

Research output: Contribution to journalArticle

Fox, Christine K. ; Keet, Corinne ; Strober, Jonathan B. / Recent advances in infant botulism. In: Pediatric Neurology. 2005 ; Vol. 32, No. 3. pp. 149-154.
@article{3fdf29071f214f8db5cac32d50ecceea,
title = "Recent advances in infant botulism",
abstract = "Since infant botulism was first identified three decades ago, our understanding of botulinum toxins and the organisms that produce them has grown. A newer classification system now recognizes Clostridium baratii and Clostridium butyricum along with Clostridium botulinum as causative agents. Recently, increasing therapeutic use of botulinum toxins has sparked substantial new research into their mechanisms of action. This research, and some case reports from infants sickened by unusual botulinum toxins suggest that disease caused by different toxin types may result in varying clinical presentations. Perhaps most significantly for pediatricians and child neurologists, a specific treatment for infant botulism has just been approved. This article reviews the clinical presentation, diagnosis, and treatment of infant botulism, including human botulism immune globulin, and discusses the various organisms and toxins that cause this disease.",
author = "Fox, {Christine K.} and Corinne Keet and Strober, {Jonathan B.}",
year = "2005",
month = "3",
doi = "10.1016/j.pediatrneurol.2004.10.001",
language = "English (US)",
volume = "32",
pages = "149--154",
journal = "Pediatric Neurology",
issn = "0887-8994",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Recent advances in infant botulism

AU - Fox, Christine K.

AU - Keet, Corinne

AU - Strober, Jonathan B.

PY - 2005/3

Y1 - 2005/3

N2 - Since infant botulism was first identified three decades ago, our understanding of botulinum toxins and the organisms that produce them has grown. A newer classification system now recognizes Clostridium baratii and Clostridium butyricum along with Clostridium botulinum as causative agents. Recently, increasing therapeutic use of botulinum toxins has sparked substantial new research into their mechanisms of action. This research, and some case reports from infants sickened by unusual botulinum toxins suggest that disease caused by different toxin types may result in varying clinical presentations. Perhaps most significantly for pediatricians and child neurologists, a specific treatment for infant botulism has just been approved. This article reviews the clinical presentation, diagnosis, and treatment of infant botulism, including human botulism immune globulin, and discusses the various organisms and toxins that cause this disease.

AB - Since infant botulism was first identified three decades ago, our understanding of botulinum toxins and the organisms that produce them has grown. A newer classification system now recognizes Clostridium baratii and Clostridium butyricum along with Clostridium botulinum as causative agents. Recently, increasing therapeutic use of botulinum toxins has sparked substantial new research into their mechanisms of action. This research, and some case reports from infants sickened by unusual botulinum toxins suggest that disease caused by different toxin types may result in varying clinical presentations. Perhaps most significantly for pediatricians and child neurologists, a specific treatment for infant botulism has just been approved. This article reviews the clinical presentation, diagnosis, and treatment of infant botulism, including human botulism immune globulin, and discusses the various organisms and toxins that cause this disease.

UR - http://www.scopus.com/inward/record.url?scp=13944263306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13944263306&partnerID=8YFLogxK

U2 - 10.1016/j.pediatrneurol.2004.10.001

DO - 10.1016/j.pediatrneurol.2004.10.001

M3 - Article

C2 - 15730893

AN - SCOPUS:13944263306

VL - 32

SP - 149

EP - 154

JO - Pediatric Neurology

JF - Pediatric Neurology

SN - 0887-8994

IS - 3

ER -